GEN Exclusives

More »

The Lists

More »
Jul 24, 2012

What the Top 10 Biopharma CEOs Are Making

GEN shows you who's in the money.

What the Top 10 Biopharma CEOs Are Making

These biotech leaders are the ones bringing home the most bacon. [© Mariusz Prusaczyk - Fotolia.com]

  • #5. Eli Lilly

    John C. Lechleiter, Ph.D., Chairman, President, and CEO

    2011 Compensation: $16,370,094

    2010 Compensation: $16,504,545

    % Change: -0.8%

  • #4. Amgen

    Kevin W. Sharer, Chairman and CEO

    2011 Compensation: $18,850,311

    2010 Compensation: $21,138,133

    % Change: -10.8%

  • #3. Abbott

    Miles D. White, Chairman, CEO, and Director

    2011 Compensation: $24,010,902

    2010 Compensation: $25,564,283

    % Change: -6.1%

  • #2. Pfizer

    Ian Read, Chairman and CEO

    2011 Compensation: $25,013,348

    2010 Compensation: $17,396,112

    % Change: 43.8%

  • #1. Johnson & Johnson

    William C. Weldon, Chairman/CEO

    2011 Compensation: $26,797,939

    2010 Compensation: $28,720,491

    % Change: -6.7%

  •  

    Leave a comment by clicking the “Comments” icon below. We want to hear your thoughts!


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?